Bionano’s shares fell 0.8% after earnings, reflecting investor caution despite modest growth in consumable revenues and improved reimbursement codes; softness in software revenue and ongoing execution risks likely weighed on sentiment.

• Q1 2026 flow cell sales reached a record 8,178 units, up 17% year-over-year, with flow cells sold to existing customers up 21% YoY.
• Consumable revenue grew 20% year-over-year to $3.9 million, signaling traction in routine users and OGM focus.
• Software revenue declined sharply by 40% year-over-year to $1.2 million due to a large prior-year sale that supplied customers through 2026.
• Other revenue increased 36% year-over-year to $1.6 million, reflecting a higher proportion of recurring revenues.
• Two significant reimbursement milestones took effect, increasing payment rates for key CPT codes by up to 47%, potentially improving long-term adoption economics.